Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling

Table 1 Association between expression of CLCA2 and clinicopathological characteristics in 143 NPC patients

Clinical factor	Cases(n = 143)	CLCA2expression		P value
Clinical factor		Low	High	P value
Gendar
Male	104	53	51	0.759
Female	39	21	18
Ages
< 45	76	41	35	0.575
≥ 45	67	33	34
T stage
T1-2	35	18	17	0.965
T3-4	108	56	52
N stage
N0-1	79	42	37	0.706
N2-3	64	32	32
Clinical stage
I-II	12	5	7	0.465
III-IV	131	69	62
WHO histological classification
Differentiated non-keratinized (type 2)	3	1	2	0.03
Undifferentiated or Poorly Differentiated (type 3)	140	73	67
Local-regional relapse
NO	123	63	60	0.754
YES	20	11	9
Diatant metastasis
NO	124	60	64	0.04
YES	19	14	5
Progression
NO	107	50	57	0.038
YES	36	24	12
Death
NO	114	54	60	0.038
YES	29	20	9

Abbreviations: WHO World Health Organization,OS overall survival, DMFS distant metastasis-free survival, CI confidence interval, HR hazard ratio. Statistical significance (p < 0.05) is shown in bold

ISSN: 1756-9966